Autolus Therapeutics PLC
autolus.comWhat Do They Do?
Sells AUCATZYL, an engineered T-cell treatment for adults with a type of blood cancer, and develops T-cell therapies for other cancers and autoimmune diseases.
10-K for FY2025, filed Mar 27, 2026We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and…View ↗
AUCATZYL is a B-lymphocyte antigen CD19 (“CD19”) chimeric antigen receptor (“CAR”) T cell therapy. AUCATZYL is designed with a fast target…View ↗
In addition to AUCATZYL/obe-cel for the treatment of adult r/r B-ALL, we are advancing obe-cel in other oncology indications including…View ↗
Obe-cel is also being developed for the treatment of autoimmune indications, and we have initiated a Phase 1 trial in patients with severe…View ↗
How Do They Make Money?
Autolus is paid for AUCATZYL when Cardinal Health delivers it to and receives acceptance from a treatment center. License income comes from upfront fees, milestone payments, sales-based payments and royalties.
10-K for FY2025, filed Mar 27, 2026
$75.4M
-
10-K for FY2025, filed Mar 27, 2026
$75.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 27, 2026 |
99% |
Product revenue, net, FY2025
$74.3M Sources
|
Sold outright |
|
License
Licensed
|
1.5%
FY2022: 97%
|
License, FY2025
$1.1M Sources
|
Licensed |
Who Are Their Customers?
Patients are the product customer; Cardinal Health delivers AUCATZYL to treatment centers, while biopharmaceutical companies license binders and related know-how.
10-K for FY2025, filed Mar 27, 2026As of December 31, 2025, the Company's product revenue has solely been comprised of sales of AUCATZYL in the U.S. The Company uses Cardinal…View ↗
The Company has determined that the patient is the customer in the arrangement pursuant to ASC 606. The Company has identified a single…View ↗
On February 6, 2024, we, through our wholly owned subsidiaries, Autolus Limited and Autolus Holdings (UK) Limited entered into a License…View ↗
Do Revenues Turn Into Profits?
No. It lost $287.5M in FY2025.
10-K for FY2025, filed Mar 27, 2026
−$270.5MView ↗
10-K for FY2025, filed Mar 27, 2026
−$287.5MView ↗
10-K for FY2025, filed Mar 27, 2026
−$302.6MView ↗
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 11, 2026
Open tableView ↗
-
Aug 11, 2026
Raises 2026 product revenue guidance
Now expects $140 million to $150 million, up from $120 million to $135 million.
Sources
8-K, filed Aug 11, 2026
Executing to plan with momentum in 2026 Developing and Delivering a New Generation of T Cell Therapies 2026 Expectations & Financial…View ↗
-
Apr 16, 2026
Replaces its independent auditor
Ernst & Young LLP (UK) was dismissed and Ernst & Young LLP (US) appointed for FY2026.
Sources
8-K, filed Apr 16, 2026
On April 14, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Autolus Therapeutics plc (the “Company”)…View ↗
Launched a commercial product
The older report described its programs as clinical-stage; the latest reports AUCATZYL approved and commercialized for adult B-cell precursor leukemia.
20-F for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 27, 2026We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and…View ↗
Added autoimmune programs
The older report described programmed T-cell therapies for cancer; the latest also describes obe-cel development for autoimmune diseases, including lupus and multiple sclerosis.
20-F for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 27, 2026We are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using our broad…View ↗
Obe-cel is also being developed for the treatment of autoimmune indications, and we have initiated a Phase 1 trial in patients with severe…View ↗
Who Do They Compete With?
Competes with BMS, J&J / Janssen Biotech, Novartis, Kite/Gilead, Cabaletta, Kyverna, Juno/BMS, Cartesian, Umoja Biopharma, Capstan Therapeutics, Interius BioTherapeutics, and EsoBiotec
10-K for FY2025, filed Mar 27, 2026BMSView ↗
Loading...
